Search for "influenza"
Answer created by AI
- Like
- Disike
AI result is experimental
Generating Answer...
-
Infectious Disease (118)
-
Clinical Trials (86)
-
Covid-19 (61)
-
The next chapter of clinical trial services (31)
-
Suvoda WP (29)
-
Therapy Area (29)
-
COVID Cross-sector Impact Brief (22)
-
Drug Development (20)
-
Country Risk Report Q4 2021 - Professional Services (19)
-
Approvals (9)
-
Technology (9)
-
API Manufacturers (7)
-
Genomics (7)
-
Cytiva-Cell & Gene Therapy WP 2 (5)
-
Respiratory (5)
-
Agilent WP (4)
-
Global Healthcare and Pharma Market Outlook (4)
-
Business & Regulation (3)
-
Immunology (3)
-
Regulation (3)
-
News Analysis and Comments (158)
-
Clinical Trials (2)
No Filter Selected
-
United States (57)
-
Australia (8)
-
United Kingdom (7)
-
India (6)
-
Japan (6)
-
Europe (5)
-
Global (4)
-
North America (4)
-
China (3)
-
Brazil (2)
-
Germany (2)
-
Middle East & Africa (2)
-
Argentina (1)
-
Asia-Pacific (1)
-
Canada (1)
-
Mexico (1)
-
Panama (1)
-
Poland (1)
-
Slovakia (1)
-
South Africa (1)
No Filter Selected
-
Other Innovation Areas (1)
No Filter Selected
Development of universal vaccines represents an emerging trend in influenza
Universal influenza vaccines are created to provide protection against more strains of the virus than the quadrivalent influenza vaccines.
WHO trivalent recommendations expected to reshape global influenza vaccine market
The World Health Organization (WHO) has recently advised a reversion to trivalent (three-strain) influenza vaccines for the 2024 southern hemisphere influenza season, which will begin around April and last until September.
Doherty and Kirby Institute study antibody-based therapy for influenza B
The researchers revealed insights on the complex mechanisms underlying antibody-based therapies for the patients.
IDWeek 2019: Seasonal influenza vaccines prove their worth, but better vaccines are still needed
Annual vaccinations reduced the number of hospitalisations in children by 50%, not only in patients with pre-existing conditions but also in healthy children (40% of the cases).
2023-24 seasonal flu activity remains elevated
GlobalData epidemiologists forecast more than 470,000 cases of lab-confirmed influenza in the US in 2024.
Seasonal influenza extends later than previous seasons
The 2021–22 influenza season has had an unusually high amount of activity late in the season, with two peaks in positive tests.
Snapshot H1N1 (swine influenza) – the post-pandemic pipeline
Few modern pandemics created as much global furore as the H1N1 swine flu outbreak which struck in 2008. The scale and spread of the outbreak created a very real sense of fear about mutating virus strains and created a boom for a new pipeline of vaccines and antivirals. Using detailed market data, we find out what the future holds for the industry in this post-pandemic period.
CureVac highlights shift in seasonal influenza vaccines development pipeline
During the past ten reported US influenza seasons, vaccine effectiveness was approximately 40%, but reached as low as 19% in 2014-2015.
National Immunization Awareness Month a reminder for seasonal influenza vaccinations
NIAM comes at an opportune time, as annual influenza vaccinations will begin to be available in the coming weeks.
Novavax begins Phase II study for Covid-19-Influenza vaccines
The trial will assess the safety and effectiveness of various formulations of CIC and flu vaccine candidates.
CDC Findings: 2021-22 US flu vaccine efficacy is concerningly low
The currently available flu vaccines protect the population against the four most common influenza viruses in circulation: A(H1N1)pdm09, A(H3N2), B/Victoria…
Moderna doses first subjects in Phase I/II trial of influenza vaccines
The trial will enrol 560 participants to assess safety, reactogenicity and immunogenicity of mRNA-1020 or mRNA-1030 vaccines.
Moderna doses first subjects in Phase III influenza vaccine trial
The trial will assess the safety and immunological non-inferiority of the mRNA-1010 vaccine in adults.
Vir Biotechnology’s PENINSULA trial fails to meet efficacy endpoints
A non-statistically significant reduction of nearly 16% in influenza A protocol-defined illness was observed.
Theraclone Sciences begins Phase II study of TCN-032
Therapeutic antibody discovery and development company Theraclone Sciences has begun a Phase II viral challenge clinical study of TCN-032, a monoclonal antibody, for the treatment of Influenza A.
NIAID starts subject enrolment in mRNA universal influenza vaccine trial
The study will compare the immunogenicity of the candidate vaccine against quadrivalent seasonal influenza vaccine.
Biota releases top-line results from Phase II trial of laninamivir octanoate
US-based Biota Pharmaceuticals has reported top-line data from a Phase II clinical trial comparing the safety and efficacy of a 40mg and 80mg dose of laninamivir octanoate (LANI) with placebo.
FluGen begins Phase I trial of H3N2 RedeeFlu universal vaccine for influenza
US-based biopharmaceutical company FluGen has begun the first Phase I clinical trial of H3N2 RedeeFlu universal vaccine for influenza.
Viriom outlines plans for upcoming infectious disease trials
Viriom will initiate two Australia-based Phase I trials investigating its assets in influenza and Covid-19 in 2024, which may lead to studies in the US.
Cocrystal selects hVIVO as CRO for Phase IIa Influenza antiviral trial
The trial of CC-42344 in participants who are challenged with influenza A is planned to begin in the second half of next year.